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Improved results using Onyx glue for the
treatment of persistent type 2 endoleak after
endovascular aneurysm repair
Christopher J. Abularrage, MD,a,b Virendra I. Patel, MD,a Mark F. Conrad, MD, MMSc,a
Eric B. Schneider, PhD,c Richard P. Cambria, MD,a and Christopher J. Kwolek, MD,a Boston, Mass; and
Baltimore, Md
Objective: Persistent type 2 (PT2) endoleaks (present>6 months) after endovascular aneurysm repair are associated with
adverse outcomes, and selective secondary intervention is indicated in those patients with an expanding aneurysm sac.
This study evaluated the outcomes of secondary intervention for PT2.
Methods: From 1999 to 2007, 136 patients who underwent endovascular aneurysm repair developed PT2 and comprised
the study cohort. Primary end points included PT2 resolution (secondary interventional success) and survival, and were
evaluated using multiple logistic regression and Kaplan-Meier analyses, respectively.
Results: Fifty-one patients underwent a total of 68 secondary interventions for PT2 with expanding aneurysm sacs with
a median postsecondary interventional follow-up of 13.7 months. Secondary interventions included 20 inferior
mesenteric artery coil embolizations, 17 Onyx glue embolizations, 11 aneurysm sac coil embolizations, 10 non-Onyx glue
embolizations, 7 lumbar artery coil embolizations, 2 open lumbar ligations, and 1 graft explant. The overall secondary
interventional success rate was 43% (29 of 68). Onyx glue embolization was associated with a greater success rate when
used as the initial secondary intervention (odds ratio, 59.61; 95% confidence interval, 4.78-742.73; P< .001). There was
no difference in success between the different techniques when multiple secondary interventions were required. Five-year
survival was 72%  0.08% and was unrelated to any of the secondary interventional techniques.
Conclusions: Secondary intervention for PT2 is associated with success in less than half of all cases. Onyx glue
embolization was associated with greater long-term success when used as the initial secondary intervention. (J Vasc Surg
2012;56:630-6.)
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sEndovascular aneurysm repair (EVAR) is an established
therapy for the treatment of abdominal aortic aneurysms
(AAAs) with suitable anatomy. EVAR has been associated
with a 65% to 70% reduction in the 30-day mortality
compared to open AAA repair.1,2 Although the Open
versus Endovascular Repair (OVER) trial demonstrated a
lower aneurysm-related mortality of EVAR compared with
open AAA repair at 2 years,3 other studies have found that
this early advantage inmortality is lost on long-term follow-
up.4-6
The equalization of mortality over time has led to a
greater scrutiny of the long-term outcomes of EVAR and
the need for secondary intervention. EVAR requires con-
tinued surveillance, as up to 11% of patients require second-
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630ry intervention for graft-related complications, in particu-
ar endoleaks.7 Recent long-term follow-up of the EVAR I
nd EVAR II trials demonstrated a 74% freedom from
econdary intervention at 8 years.6 Although the presence
f type 1 and 3 endoleaks is a clear indication for secondary
ntervention, the clinical significance of type 2 endoleaks
as not been completely established.
Type 2 endoleaks occur in 10% to 30% of patients after
VAR and may be associated with aneurysm growth and
upture.8,9 Subdivision of type 2 endoleaks into transient
resolving within 6months) and persistent (present beyond
months) has been found to predict EVAR-related com-
lications. Persistent type 2 (PT2) endoleaks have been
ssociated with an increased incidence of adverse outcomes,
ncluding aneurysm sac growth, secondary intervention
ate, the need for conversion to open repair, and rupture.10
n addition, long-term surveillance and secondary interven-
ion are associated with increased costs after EVAR.11
ccordingly, the success of secondary interventions is an
mportant clinical goal. The purpose of this study was to
valuate the results of secondary intervention for PT2 over
10-year period at a single academic medical center.
ETHODS
All EVARs performed between January 1999 and De-
ember 2007 were retrospectively identified from a pro-
pectively maintained database. The study was approved by
he Institutional Review Board of the Massachusetts General
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Volume 56, Number 3 Abularrage et al 631Hospital. Exclusion criteria included patients with thoracic
aortic aneurysms, anastomotic aneurysms, isolated iliac artery
aneurysms, and patients with6 months’ follow-up.
Preoperative data collection was obtained from the
patient hospital and office charts and included demograph-
ics, medical history, and laboratory results. Estimated glo-
merular filtration rate was calculated according to theMod-
ification of Diet in Renal Disease Study.12 Chronic renal
insufficiency was defined as a glomerular filtration rate
60, or chronic kidney disease stages 3 to 5.13
All preoperative and postoperative computed tomogra-
phy (CT) scans were reviewed by an attending radiologist,
an attending vascular surgeon, and a vascular fellow. Pa-
tients underwent preoperative CT scan imaging with 2.0-
to 2.5-mm cuts. Preoperative anatomic variables included
maximum aneurysm diameter, maximum aneurysm lumi-
nal diameter, aneurysm sac volume, patency of the inferior
mesenteric artery (IMA), number of patent lumbar arteries,
occlusion of internal iliac vessels (chronic or via preopera-
tive embolization), and percent of aneurysm sac thrombo-
sis. The maximum aneurysm luminal diameter was defined
as the shortest diagonal of the contrast opacified lumen
measured on the same cross-sectional CT image with the
maximum aneurysm diameter. Aneurysm sac volume was
calculated based on M2S (M2S Inc, West Lebanon, NH)
three-dimensional imaging total aneurysm volume to the
right hypogastric artery in cubic centimeters. Thrombus
load was defined as the area of the aneurysm sac measured
on the same cross-sectional CT image with the maximum
aneurysm diameter minus the maximum aneurysm luminal
area. Percent of sac thrombosis was calculated by the
method of Sampaio et al14 and was defined as the ratio of
the area of the thrombus load to that of the aneurysm sac.
All patients in the study received a follow-up CT scan
with intravenous contrast and thin collimation 6 months
postoperatively. After a nonenhanced CT scan was per-
formed, a bolus injection of contrast was administered at 4
mL/s with a 25-second preparation delay. Delayed phase
images were then obtained, and images were reconstructed
with 2.0- to 2.5-mm cuts. The presence of a type 2 en-
doleak was determined by the radiologist and/or surgeon
and was corroborated in blind fashion by a study vascular
surgeon and/or fellow. Arteriography was performedwhen
it was not possible to differentiate between different types
of endoleaks. PT2 was defined as any type 2 endoleak
present 6 months postoperatively and included late-
appearing type 2 endoleaks that were not present before 6
months. Further follow-up imaging with CT angiography
was typically obtained at 6-month to 1-year intervals.
The preferred method of treatment changed over time
due to the availability of new treatment modalities. A more
aggressive approach to these patients was taken as we
learned of the adverse late outcomes associated with PT2
and aneurysm sac growth. Presecondary intervention ana-
tomic variables included maximum aneurysm diameter,
aneurysm sac volume, patency of the IMA, and number of
patent lumbar arteries. iTreatment modalities included coil embolization of the
neurysm sac, lumbar arteries, or IMA; direct sac injection
f Onyx (ev3 Inc, Irvine, Calif) or non-Onyx glue; open
umbar artery ligation; and graft explant. Access to the
neurysm was achieved by several methods: (1) direct
ranslumbar puncture of the aneurysm sac with the patient
n the right lateral decubitus position with placement of a
F MAK-NV-006 mini-access trocar (Merit Medical Sys-
ems Inc, South Jordan, Utah); (2) via a retrograde brachial
r femoral artery approach to the superior mesenteric artery
ith access to the IMA via the meandering mesenteric
rtery using a 0.021 microcatheter; or (3) using a 0.021
icrocatheter via collateral vessels from the hypogastric
rtery. The size and number of coils used were at the
ttending surgeon’s discretion. Direct sac puncture allowed
he placement of larger 0.035 fiber coils (Cook Medical
nc, Bloomington, Ind) through a 4F catheter. Both de-
achable and pushable 0.018 coils (Cook Medical Inc) were
sed through the 0.021 microcatheters. Non-Onyx glue
reatment included Gelfoam pellets (Pfizer Inc, New York,
Y) combined with Thrombin (King Pharmaceuticals Inc,
ristol, Tenn), Bioglue (Cryolife Inc, Kennesaw,Ga), and/or
-butyl-2-cyanoacrylate (Cordis Inc, Miami Lakes, Fla).
Onyx is a liquid embolic agent ethylene vinyl alcohol
EVOH) copolymer dissolved in dimethyl sulfoxide
DMSO) and is approved for use in the United States with
n indication for the treatment of intracranial aneurysms. It
omes in two formulations: Onyx 18 (6% EVOH) and
nyx 34 (8% EVOH). Onyx 18 has a lower viscosity and,
herefore, may flow farther in the endoleak cavity. Both
ormulas solidify within 5 minutes of injection.
Onyx glue treatment required placement of an Echelon
4 microcatheter (ev3 Inc), which is compatible with the
MSO used as a component of Onyx. A failed attempt was
efined as an unsuccessful endovascular attempt at access-
ng the endoleak cavity.
Postsecondary intervention anatomic variables in-
luded maximum aneurysm diameter, aneurysm sac vol-
me, patency of the IMA, and number of patent lumbar
rteries. Secondary interventional success was defined as
esolution of the PT2.
Continuous variables are reported as mean  SEM.
nivariate comparisons of patient demographic and risk
actors and anatomic variables were performed using 2 or
isher exact test and unpaired t-tests, when appropriate.
urvival analysis was performed using the Cox-Mantel test
f the Kaplan-Meier survival estimates. Certain patients had
ore than one intervention and, thus, interventional out-
omes in these patients were not independent. Therefore,
he cohort was stratified into two groups: the initial second-
ry intervention and subsequent secondary interventions.
his was performed to account for the fact that outcomes
ight not be independent due to either demographic
actors within the patient or factors related to the nature of
hat patient’s PT2. Logistic regression analysis was per-
ormed on the stratified groups using all variables with P
10 on univariate analysis. Procedure year was also included
n the multivariable analysis because Onyx was not available
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tailed) were considered significant. Analyses were per-
formed using StatView software (SAS Inc, Cary, NC).
RESULTS
During the study period, EVAR was performed in 832
patients. Overall results from our EVAR experience have
been published previously.15 Five hundred ninety-five of
the 832 patients underwent follow-up CT scans 6
months postoperatively. PT2 was identified in 136 patients
who comprised the study cohort. Fifty-one patients (38%)
underwent a total of 68 secondary interventions for PT2
with expanding aneurysm sacs with amedian postsecondary
interventional follow-up of 13.7 months. Of the 68 sec-
ondary interventions, 3 were open surgical and 65 were
endovascular procedures. Endovascular patients were di-
vided into two cohorts depending on whether they under-
went Onyx glue embolization (Onyx, n  17) or not
(non-Onyx, n  48).
Preoperative patient characteristics and anatomic vari-
ables are summarized in Table I. The Onyx group tended
Table I. Preoperative characteristics and anatomic
variables
Onyx Non-Onyx
P
value
No. of patients 17 48
Preoperative comorbidities
Age, yearsa 73.6  2.0 79.1  0.8 .004
Male gender 16 (94%) 41 (84%) .43
Tobacco use 13 (76%) 33 (67%) .55
Hypertension 15 (88%) 43 (88%) .99
Coronary artery disease 10 (59%) 12 (24%) .02
Diabetes mellitus 1 (6%) 8 (16%) .43
Chronic renal insufficiency 4 (24%) 22 (45%) .16
COPD 2 (12%) 8 (16%) .99
Atrial fibrillation 3 (18%) 16 (33%) .35
Hypercholesterolemia 14 (82%) 25 (51%) .04
Medications
Aspirin 11 (65%) 22 (45%) .26
Clopidogrel 4 (24%) 3 (6%) .07
Warfarin/anticoagulation 2 (12%) 9 (18%) .71
Pre-EVAR CT scan
Patent IMA 17 (100%) 49 (100%) NC
Patent lumbar arteriesa 7  0 7  0 .49
MALD 30 13 (76%) 33 (67%) .99
Lumen diameter, mma 42  3 38  2 .31
Sac diameter (mm)a 56  2 54  1 .47
Sac volume (cc)a 196  13 174  10 .18
Presecondary intervention
CT scan
Patent IMA 12 (71%) 43 (88%) .13
Patent lumbar arteriesa 6  0 6  0 .43
Sac diameter, mma 60  2 58  1 .26
Sac volume, cca 241  20 212  11 .2
COPD, Chronic obstructive pulmonary disease; CT, computed tomogra-
phy; EVAR, endovascular abdominal aortic aneurysm repair; IMA, inferior
mesenteric artery; MALD, maximum aneurysm luminal diameter; NC, not
calculated.
aMean  SEM.to be younger (73.6  2.0 vs 79.1  0.8 years; P  .004) Tnd had a higher incidence of coronary artery disease (59%
s 24%; P  .02) and hypercholesterolemia (82% vs 51%;
 .04). There were no statistically significant differences
n the preoperative or presecondary intervention CT scan
easurements between the Onyx and the non-Onyx
roups. Eighty percent of patients undergoing secondary
ntervention for PT2 had sac enlargement.
The long-term success rate was 38% (29 of 77) in all
econdary interventions for PT2. When excluding failed
ttempts at accessing the endoleak cavity (n  9), the
ong-term success rate of secondary intervention was 43%
29 of 68). Finally, when excluding open surgical second-
ry interventions, the long-term success rate of endovascu-
ar secondary intervention was 40% (26 of 65; Table II).
he mean change in aneurysm sac diameter from presec-
ndary intervention to maximum follow-up was decreased
n the Onyx glue embolization group (2 1 vs 3 1mm
on-Onyx).
Excluding failed attempts, a total of 13 patients (20%)
equired more than one secondary endovascular interven-
ion, one of whom required more than two secondary
nterventions for persistently expanding aneurysm sac. Of
he 14 subsequent secondary endovascular interventions
or recurrent type 2 endoleak, only one was performed for
failure of Onyx glue embolization.
Upon stratification of the cohort, there were 51 initial
econdary interventions and 14 subsequent secondary in-
erventions. On univariate analysis of the initial secondary
ntervention (Table III), Onyx glue embolization was as-
ociated with a greater long-term success rate (91% vs 23%;
 .001). Univariate analysis of subsequent secondary
nterventions did not find any statistically significant differ-
nces in long-term success between those who received
nyx glue embolization and those who did not (P  1.0;
able II. Long-term secondary interventional success of
ndovascular interventions for PT2 endoleak
Procedures,
No.
Long-term
success
ndovascular secondary interventions 65 26 (40%)
Onyx glue 17 13 (76%)
Lumbar coil embolization 7 3 (43%)
Sac coil embolization 11 4 (36%)
IMA coil embolization 20 4 (20%)
Non-Onyx glue 10 2 (20%)
MA, Inferior mesenteric artery; PT2, persistent type 2.
able III. Univariate analysis of long-term
nterventional success of initial secondary intervention
ndovascular secondary
nterventions
Procedures,
No.
Long-term
success
P
value
nyx glue 11 10 (91%) .001
on-Onyx embolization 40 9 (23%)able IV). Multivariable logistic regression analysis of the
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embolization was the only examined factor associated with
long-term success (odds ratio, 59.61; 95% confidence in-
terval, 4.78-742.73; P  .001; Table V).
In the entire cohort, 5-year survival was 72%  0.08%
and was independent of any specific secondary interven-
tional technique. Specifically, there were no statistically
significant differences in survival between the Onyx and
non-Onyx groups at 4 years (92% 0.08% vs 82% 0.07%;
P  .84; Fig 1). No patients developed a ruptured aneu-
rysm in the follow-up period.
DISCUSSION
Randomized trials have shown an early survival benefit
of EVAR compared to open AAA repair, making EVAR the
preferred treatment of AAAs with suitable anatomy.2,16
However, only the OVER trial found that this early benefit
in overall mortality extended beyond 2 years postopera-
tively.3 Long-term costs of EVAR related to obligatory
surveillance can be significant17 and are only exacerbated by
the costs of secondary interventions.18
The need for secondary intervention after EVAR ranges
from 11% to 19% and is accounted for by the presence of
type 2 endoleaks in up to 40% of these cases.7,19 Thus, type
2 endoleaks are the most common indication for secondary
intervention. Type 2 endoleaks were previously believed to
be of minor significance, but recent evidence suggests that
this may not be the case. We have previously shown that
PT2 endoleaks are associated with aneurysm sac expansion
and rupture.8-10
The timing of secondary intervention for type 2 en-
doleaks has been the subject of much debate. Some have
argued that preoperative branch vessel management to
prevent type 2 endoleaks can decrease the risk of adverse
outcomes.20 Results from our overall experience suggest
Table IV. Univariate analysis of long-term interventional
success of subsequent secondary interventions
Endovascular secondary
interventions
Procedures,
No.
Long-term
success
P
value
Onyx glue 6 3 (50%) 1
Non-Onyx embolization 8 4 (50%)
Table V. Multivariable logistic regression of long-term
interventional success of initial secondary intervention
OR 95% CI P value
Onyx glue 59.61 4.78-742.73 .001
Procedure year 0.83 0.63-1.08 .17
Coronary artery disease 2.11 0.37-12.12 .4
Age 0.95 0.84-1.08 .45
Hypercholesterolemia 0.69 0.11-4.14 .68
Clopidogrel 0.83 0.02-34.63 .92
CI, Confidence interval; OR, odds ratio.that this is unnecessary, because only 7% of patients re- muired secondary intervention for PT2 and 93% of patients
ould have undergone an unnecessary procedure.21 We,
herefore, use a strategy of selective secondary intervention
or type 2 endoleaks in the presence of aneurysm sac
xpansion and persistence beyond 6 months postopera-
ively.
Access to the aneurysm sac can be achieved via multiple
pproaches and is patient-specific. The location of the
ndoleak on CT scan dictates the access that is chosen. If
he IMA is involved, then a superior to IMA access via the
arginal artery of Drummond may be chosen. If the en-
oleak involves only the lumbar arteries, then a transfemo-
al or a hypogastric approach can be used. Translumbar
ccess is frequently employed for all types of PT2 because it
ives direct access to the aneurysm sac.
The method of PT2 secondary intervention changed
ver the course of the 10-year study period. This was due,
n part, to the commercial availability of the different tech-
iques and our experience with endoleak management.
arly on, we performed direct sac puncture with coil em-
olization into the aneurysm sac or the placement of other
mbolic materials, such as thrombin and gelfoam adjacent
o the feeding vessels. Although these procedures initially
eemed to decrease flow, they were often unsuccessful
ecause we could not directly cannulate all of the feeding
essels. This led to recanalization of the endoleak cavity
hrough the formation of new flow channels. In addition,
irect coil embolization of feeding lumbar vessels is not
lways technically possible. This led us to seek a more
eliable method to obliterate flow.
Our current technique involves obtaining aneurysm sac
ccess with subsequent placement of a DMSO-compatible
icrocatheter directly into the flow channel of the en-
oleak, which is confirmed by contrast injection. After
ushing with saline to clear the catheter of all blood, the
ead space of the catheter is replaced with DMSO. Onyx is
hen injected and allowed to fill both the flow channel
ithin the aneurysm sac and the feeding vessels.
Onyx 34 is initially injected into the endoleak cavity of
he aneurysm sac and inherently propagates with the flow of
lood, ultimately solidifying and plugging the endoleak
hannel. Once we have a cast of the feeding vessels and are
omfortable with how quickly the Onyx travels, we switch
o Onyx 18, which is less viscous. Thus, Onyx addresses
oth the aneurysm sac endoleak cavity as well as the in-
olved aortic branch vessels. Previous studies have found
mproved success when the endoleak cavity is addressed in
ddition to the branch vessels.22 Furthermore, aneurysm
ac coil embolization may be extensive, requiring a large
umber of expensive coils. This may greatly increase the
ost of secondary intervention with little improvement in
uccess rates, as isolated aneurysm sac coil embolization in
he current study was associated with a 36% long-term
uccess rate. We also found that direct injection of Onyx
nto the aneurysm sac, without first identifying the flow
hannel, was not effective in treating the endoleak.
Onyx is suspended in micronized tantalum powder
aking it radio-opaque during angiography. Thus, we
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angiography to know that we have successfully treated the
endoleak (Fig 2). This may result in considerable streak
artifact on follow-up CT scan imaging; however, continued
measurement of the aneurysm sac size is possible. One can
also appreciate a cast of the endoleak cavity and feeding
Fig 1. Kaplan-Meier survival curv
Fig 2. Translumbar angiogram after coil and Onyx emboliza-
tion demonstrating cast of feeding lumbar vessels and endoleak
cavity.vessels on plain X-ray or CT reconstruction (Fig 3). Post- orocedure imaging is mandatory to evaluate the success of
econdary intervention.
Endoleak recurrence is a common problem after sec-
the Onyx and non-Onyx groups.
ig 3. Anteroposterior radiograph demonstrating Onyx cast of
ndoleak cavity and feeding lumbar vessels.ndary intervention. In the current study, this occurred in
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result. Other series have found a 10% to 60% recurrence of
type 2 endoleaks after secondary intervention.19,23,24 This
is most likely a difference in techniques because results
improved throughout the course of the study. Over the
study period, we also identified the ineffectiveness of iso-
lated IMA coil embolization. Although this is a relatively
easy technique, it frequently converts an IMA-to-lumbar
endoleak into a lumbar-to-lumbar endoleak.22 Other
causes of embolization failure may include persistent flow
through poorly packed coils, or the development of a
retiform anastomosis around coiled vessels.24 We did note
recanalization of IMA vessels previously treated with coil
embolization and have now changed toOnyx embolization
of the IMA. This allows us to treat not only the IMA, but
also a feeding lumbar vessel at the same setting. If there are
multiple pairs of lumbar vessels at different levels or a patent
IMA and lumbar vessels separated by a great distance, a
second treatment session may be required to access another
part of the sac (Fig 4).
Endoleak recurrence may be difficult to identify in the
presence of either coils or an Onyx cast, as both cause a
great deal of scatter on follow-up CT angiography. How-
ever, we have found that accurate sac diameter measure-
ments are not inhibited by the scatter. When combined
with duplex ultrasonography scan, recurrent flow within
the sac causing sac expansion can be estimated with reason-
able certainty.
Although the use of Onyx glue did result in the greatest
success rates, one limitation of the technique is cost. Onyx
is currently provided in 1-mL vials which cost approxi-
mately $2500 each. Over the study period, we changed our
technique to use fewer vials at the initial secondary inter-
vention with a focus on occluding the outflow vessels. This
can often be combined with the use of large coils to partially
occlude the flow channel within the aneurysm sac and
decrease overall cost. We will also intentionally plan to
bring patients back for repeat Onyx glue injections at a later
date if feeding vessels are identified at multiple sites rather
Fig 4. A, Initial angiogram of inferior mesenteric-to-lu
mesenteric to inferior mesenteric artery approach. B, Po
demonstrating conversion to a lumbar-to-lumbar endole
endoleaks.than try to fill a large aneurysm cavity with Onyx alone. mIt is interesting that Onyx glue embolization was asso-
iated with long-term success when used as the initial
econdary intervention, but not when used in the treatment
f a failed secondary intervention. No studies examining
he long-term effects of Onyx exist in the literature to help
xplain this discrepancy. It may represent a difference in the
haracteristics of the PT2 itself. A prospective trial of Onyx
ould be necessary to tease out these details, because the
nalysis was limited by a small number of patients who
equired more than one secondary intervention.
In the current study, survival did not differ among the
ifferent techniques. This likely represents the fact that the
isk of rupture, which increased in the presence of PT2, is
elatively low; thus, identification and treatment of PT2
ith continued close follow-up results in excellent overall
urvival. Because Onyx was a relatively new aspect of our
reatment paradigm, it remains to be seen if the increased
osts justify its use. Based on the stratification of the sec-
ndary interventions, it may only be worthwhile to use
nyx at the initial secondary intervention.
The current study represents one of the largest cohorts
ndergoing secondary intervention specifically for PT2.
ur results must be viewed with caution. There were a
umber of diverse techniques used to treat PT2 over a long
eriod of time. Thus, factors other than those studied may
ccount for the results. The decision to intervene with a
articular endovascular technique was surgeon-specific and
riven predominantly by the experience of one senior in-
erventionalist (C.K.) over the study period. A patient may
ave been a candidate for multiple techniques, but these
ere not randomized over the study period. Any differ-
nces seen in the current study must be confirmed in a
andomized study.
In conclusion, secondary intervention for PT2 is asso-
iated with success in less than half of all cases. There was an
ncreased rate of success with the use of Onyx glue embo-
ization at the initial secondary intervention, although
urvival was not predicted by any of the secondary interven-
ional techniques. Further study of Onyx for the manage-
artery type 2 endoleak treated with Onyx via a superior
ondary intervention computed tomography (CT) scan
rrow). C, Angiogram demonstrating Onyx cast of bothmbar
stsec
ak (aent of endoleak seems warranted, with the hope that a
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formed in the near future.
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